Cost-effectiveness of interferon-γ release assay testing for the treatment of latent tuberculosis

European Respiratory Journal

Volumn 30, Issue 2, 2007, Pages 321-332

  Diel, Roland ^a   Wrighton Smith, P ^b   Zellweger, J P ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Oxford Immunotec   (United Kingdom)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cost effectiveness; Interferon release assay; Latent tuberculosis infection; Latent tuberculosis infection treatment; Tuberculosis

Indexed keywords

ETHAMBUTOL; GAMMA INTERFERON; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; RIFATER;

ADULT; AGE DISTRIBUTION; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; DIAGNOSTIC VALUE; DRUG COST; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; INTERMETHOD COMPARISON; LUNG TUBERCULOSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE PAYMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SWITZERLAND; TUBERCULIN TEST;

ADULT; ANTITUBERCULAR AGENTS; CARRIER STATE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; INTERFERON TYPE II; MALE; MARKOV CHAINS; MASS SCREENING; PROBABILITY; SENSITIVITY AND SPECIFICITY; SOFTWARE; SWITZERLAND; TUBERCULIN TEST; TUBERCULOSIS;

EID: 34547557038     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00145906     Document Type: Article

References (35)

1. Broekmans JF, Migliori GB, Rieder HL, et al. European framework for tuberculosis control and elimination in countries with a low incidence. Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Association (KNCV) Working Group. Eur Respir J 2002; 19: 765-775.
2. Ewer K, Deeks J, Alvarez L, et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361: 1168-1173.
3. Zellweger JP, Zellweger A, Ansermet S, de Senarclens B, Wrighton-Smith P. Contact tracing using a new T-cell-based test: better correlation with tuberculosis exposure than the tuberculin skin test. Int J Tuberc Lung Dis 2005; 9: 1242-1247.
4. Diel R, Ernst M, Döscher G, et al. Avoiding the effect of BCG vaccination in detecting Mycobacterium tuberculosis infection with a blood test. Eur Respir J 2006; 28: 16-23.
5. Shams H, Weis S, Klucar P, et al. Enzyme-linked immunospot and tuberculin skin testing to detect latent tuberculosis infection. Am J Respir Crit Care Med 2005; 172: 1161-1168.
6. Richeldi L, Ewer K, Losi M, et al. T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure. Am J Respir Crit Care Med 2004; 170: 288-295.
7. Piana F, Codecasa LR, Cavallerio P, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006; 28: 31-34.
8. Diel R, Nienhaus A, Lange C, Schaberg T. Cost-optimisation of screening for latent tuberculosis in close contacts. Eur Respir J 2006; 28: 35-44.
9. Wrighton-Smith P, Zellweger J-P. Direct costs of three models for the screening of latent tuberculosis infection. Eur Respir J 2006; 28: 45-50.
10. Swiss Lung League. Erkennung der Tuberkuloseinfektion mittels Bluttest (Interferon-gamma). [Detection of tuberculous infection by a blood-test (interferon-gamma).] Bern, Lungenliga Schweiz, October 2005 (updated December 19, 2005).
11. Lee JY, Choi HJ, Park I-N, et al. Comparison of two commercial interferon-γ assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006; 28: 24-30.
12. Lalvani A, Pathan A, McShane H, et al. Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am J Respir Crit Care Med 2001; 163: 824-828.
13. Ferrara G, Losi M, D'Amico R, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 2006; 367: 1328-1334.
14. Diel R, Nienhaus A, Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts. Eur Respir J 2005; 26: 465-473.
15. Chapman A, Munkanta M, Wilkinson K, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16: 2285-2293.
16. Pathan AA, Wilkinson KA, Klenerman P, et al. Direct ex vivo analysis of antigen-specific IFN-γ-secreting CD4-T cells in Mycobacterium tuberculosis-infected individuals; associations with clinical disease status and effect of treatment. J Immunol 2001; 167: 5217-5255.
17. Lalvani A, Nagvenkar P, Udwadia Z, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infectious Dis 2001; 183: 469-477.
18. Meier T, Eulenbruch HP, Wrighton-Smith P, Enders G, Regnath T. Sensitivity of a new enzyme-linked immunospot assay (T SPOT-TB) for diagnosis of tuberclosis in clinical practice. Eur J Microbiol Infect Dis 2005; 24: 529-536.
19. Swiss Federal Statistical Office. Sterbetafeln für die Schweiz 1998/ 2003. [Mortality Tables for the Swiss 1998/2003.] Bern, Swiss Federal Statistical Office, 2005.
20. Swiss Federal Statistical Office. Individual assessment.
21. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-2079.
22. Swiss Lung League-Swiss Federal Statistical Office. Handbuch Tuberkulose. [Tuberculosis Handbook]. Schweiz Med Forum 2003; 3: 487-491.
23. Swiss Federal Office of Public Health. Bulletin 20/06. Communicable Diseases. Tuberculosis in the Swiss 2001-2004. Bern, Swiss Federal Office of Public Health, 2006; p. 428.
24. Nicolet G, Rochat T, Zellweger JP. Traitement de la tuberculose. [Treatment of tuberculosis.] Swiss Medical Forum 2003; 22: 506-516.
25. Hanoverian consensus group. German revised recommendations on health economic evaluation. Deutsch Med Wochenschr 1999; 124: 1503-1506.
26. Swiss Federal Statistical Office. Löhne, Erwerbseinkommen - Indikatoren. [Salaries and earnings: indicators.] www.bfs.admin.ch/bfs/ portal/de/index/themen/03/04/blank/key/erwerbseinkommen.html. Date last updated: May 8, 2007. Date last accessed: May 8, 2007.
27. Swiss Federal Statistical Office. Taschenstatistik der Schweiz, Arbeit. [Statistical data on Switzerland 2006. Work.] Bern, Swiss Federal Statistical Office, 2006; p. 8.
28. Owens DK. Interpretation of cost-effectiveness analyses. J Gen Intern Med 1998; 13: 716-717.
29. Doherty TM, Demissie A, Olobo J, et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 2002; 40: 704-706.
30. Fallab-Stubi CL, Zellweger JP, Sauty A, Uldry C, Iorillo D, Burnier M. Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis. Int J Tuberc Lung Dis 1998; 2: 525-530.
31. Nunn P, Williams B, Floyd K, Dye C, Elzinga G, Raviglione M. Tuberculosis control in the era of HIV. Nat Rev Immunol 2005; 5: 819-826.
32. Harries AD, Boxshall M, Phiri S, Kwanjana J. Managing HIV and tuberculosis in sub-Saharan Africa. Lancet 2006; 367: 1817-1818.
33. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004; 1: CD000171.
34. Shrestha RK, Mugisha B, Bunnell R, et al. Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda. Int J Tuberc Lung Dis 2006; 10: 656-662.
35. Mugisha B, Bock N, Mermin J, et al. Tuberculosis case finding and preventive therapy in an HIV voluntary counseling and testing center in Uganda. Int J Tuberc Lung Dis 2006; 10: 761-767.